RESUMEN
BACKGROUND: Direct oral anticoagulants (DOACs) are the mainstay of treatment for venous thromboembolism (VTE) and non-valvular atrial fibrillation (AF), with or without an underlying cancer. Patients with cancer have a 2-3-fold increase in risk for bleeding complications compared to non-cancer patients taking anticoagulant therapy, however the incidence of bleeding for urogenital and gynecological cancers on DOACs are uncertain. AIMS: To assess the bleeding risk associated with the use of DOACs in patients with urogenital and/or gynecological cancers. METHOD: We conducted a systematic review of randomized controlled trials (RCTs) and prospective cohort studies to address the safety of DOACs for VTE and AF when used in patients with urogenital and/or gynecological malignancy. The primary outcomes assessed were major and clinically relevant non-major (CRNMB) bleeding, with minor bleeding considered as a secondary outcome. MEDLINE, EMBASE and COCHRANE Central Registry of Controlled Trials were searched up to and including Oct 28, 2022. The study protocol was registered in PROSPERO (CRD42022370981). Studies were independently assessed for inclusion and data extracted in duplicate. RESULT: Seven studies met our inclusion criteria (Fig. 1): 2 RCTs and 5 prospective cohort studies. A total of 676 patients treated with DOACs were included, 628 (92.8%) had VTE and 48 (7.1%) had AF. In patients with VTE treated with DOACs, the pooled major bleeding rate was 2.1%, 95% confidence intervals (CI) 0.9-3.3% (Fig. 2). Pooled estimates could not be determined for AF patients given small event and patient numbers. CONCLUSION: Major bleeding rates in urogenital and/or gynecological cancer patients treated with DOACs are similar to that of the general cancer population.
Asunto(s)
Neoplasias de los Genitales Femeninos , Hemorragia , Neoplasias Urogenitales , Tromboembolia Venosa , Humanos , Femenino , Neoplasias de los Genitales Femeninos/tratamiento farmacológico , Neoplasias de los Genitales Femeninos/complicaciones , Hemorragia/inducido químicamente , Hemorragia/epidemiología , Incidencia , Tromboembolia Venosa/epidemiología , Tromboembolia Venosa/tratamiento farmacológico , Neoplasias Urogenitales/tratamiento farmacológico , Neoplasias Urogenitales/complicaciones , Administración Oral , Anticoagulantes/efectos adversos , Anticoagulantes/administración & dosificación , Anticoagulantes/uso terapéutico , Fibrilación Atrial/tratamiento farmacológico , Fibrilación Atrial/complicaciones , Adulto , Ensayos Clínicos Controlados Aleatorios como AsuntoRESUMEN
BACKGROUND AND OBJECTIVES: Acute kidney injury (AKI) has emerged as an important toxicity among patients with advanced cancer treated with immune checkpoint inhibitors. The aim of this study was to describe the incidence, risk factors and mortality of AKI in patients receiving immune checkpoint inhibitors alone or in combination with another form of immunotherapy or chemotherapy. DESIGN, SETTING AND PARTICIPANTS: We included all patients who received immune checkpoint inhibitors alone or in combination with another form of immunotherapy or chemotherapy at AC Camargo Cancer Center from January 2015 to December 2019. AKI was defined as a ≥ 1.5 fold increase in creatinine from baseline within 12 months of immune checkpoint inhibitor initiation. We assessed the association between baseline demographics, comorbidities, medications and risk of AKI using a competing risk model, considering death as a competing event. RESULTS: We included 614 patients in the analysis. The mean age was 58.4 ± 13.5 years, and the mean baseline creatinine was 0.8 ± 0.18 mg/dL. AKI occurred in 144 (23.5%) of the patients. The most frequent AKI etiologies were multifactorial (10.1%), hemodynamic (8.8%) and possibly immunotherapy-related (3.6%). The likelihood of AKI was greater in patients with genitourinary cancer (sHR 2.47 95% CI 1.34-4.55 p < 0.01), with a prior AKI history (sHR 2.1 95% CI 1.30-3.39 p < 0.01) and taking antibiotics (sHR 2.85 95% CI 1.54-5.27 p < 0.01). CONCLUSIONS: In this study, genitourinary cancer, previous AKI and antibiotics use were associated with a higher likelihood of developing AKI.
Asunto(s)
Lesión Renal Aguda , Neoplasias Urogenitales , Humanos , Adulto , Persona de Mediana Edad , Anciano , Creatinina , Inhibidores de Puntos de Control Inmunológico/efectos adversos , Lesión Renal Aguda/inducido químicamente , Lesión Renal Aguda/epidemiología , Factores de Riesgo , Inmunoterapia/efectos adversos , Neoplasias Urogenitales/complicaciones , Antibacterianos , Estudios RetrospectivosRESUMEN
BACKGROUND: To our knowledge, there is no clinical data pertaining to COVID-19 outcomes and safety of COVID-19 vaccination in Russian patients with genitourinary (GU) malignancies. Aim of our analysis was to describe the characteristics of the COVID-19 infection course as well as preliminary safety and efficacy of Gam-COVID-Vac vaccine in patients with active GU malignancies. METHODS: Patients were retrospectively identified at nine cancer centers in different regions. Patients were included if COVID-19 was diagnosed by a polymerase chain reaction. Data from additional patients with GU cancers who had no positive SARS-CoV-2 RT-PCR test before vaccination and who received two doses of Gam-COVID-Vac (Sputnik V) between 11 February and 31 August 2021 were collected for safety assessment. Anonymized data were collected through an online registry covering demographics, treatments, and outcomes. RESULTS: The Gam-COVID-Vac vaccine was well tolerated; no grade 3-5 toxicities were reported in 112 vaccinated metastatic GU cancer patients. The most common grade 1 adverse events (81%) were injection site reactions (76%), flu-like illness (68%), and asthenia (49%). Five patients experienced grade 2 chills (4.5%) and 3 patients had grade 2 fever (2.7%). With median follow-up of 6.2 months, two COVID-19 cases were confirmed by RT-PCR test in the vaccine group (of 112 participants; 1.8%). Eighty-eight patients with COVID-19 disease were included in the analysis. The average age as of the study enrollment was 66 (range 39-81) and the majority of patients were male with renal cell carcinoma (RCC). Thirty-six patients (41%) had evidence of metastatic disease, of these 22 patients were receiving systemic therapy. More than half of patients required hospitalization. Fifty-four patients (61%) experienced complications. Sixteen patients who developed COVID-19 pneumonia required mechanical ventilator support. Sixteen patients (18%) died in a median of 23.5 days after the date of COVID-19 diagnosis was established. The 3-month survival rate was 82%. Clinical and/or radiographic progression of cancer during COVID-19 infection or the subsequent 3 months was observed in 10 patients (11.4%). CONCLUSION: Patients with GU malignancies are at increased risk of mortality from COVID-19 infection when compared to the general population. Vaccination could be safe in GU cancer patients. TRIAL REGISTRATION: retrospectively registered.
Asunto(s)
Vacunas contra la COVID-19/uso terapéutico , COVID-19/complicaciones , COVID-19/prevención & control , Neoplasias Urogenitales/complicaciones , Adulto , Anciano , Anciano de 80 o más Años , COVID-19/diagnóstico , COVID-19/epidemiología , Vacunas contra la COVID-19/efectos adversos , Femenino , Humanos , Masculino , Persona de Mediana Edad , Estudios Retrospectivos , Federación de Rusia/epidemiología , SARS-CoV-2/aislamiento & purificación , Resultado del Tratamiento , Neoplasias Urogenitales/epidemiologíaRESUMEN
Urothelial cancer is the second most common cancer, and cause of cancer death, related to the genitourinary tract. The goals of surveillance imaging after the treatment of urothelial cancer of the urinary bladder are to detect new or previously undetected urothelial tumors, to identify metastatic disease, and to evaluate for complications of therapy. For surveillance, patients can be stratified into one of three groups: 1) nonmuscle invasive bladder cancer with no symptoms or additional risk factors; 2) nonmuscle invasive bladder cancer with symptoms or additional risk factors; and 3) muscle invasive bladder cancer. This document is a review of the current literature for urothelial cancer and resulting recommendations for surveillance imaging. The American College of Radiology Appropriateness Criteria are evidence-based guidelines for specific clinical conditions that are reviewed annually by a multidisciplinary expert panel. The guideline development and revision include an extensive analysis of current medical literature from peer reviewed journals and the application of well-established methodologies (RAND/UCLA Appropriateness Method and Grading of Recommendations Assessment, Development, and Evaluation or GRADE) to rate the appropriateness of imaging and treatment procedures for specific clinical scenarios. In those instances where evidence is lacking or equivocal, expert opinion may supplement the available evidence to recommend imaging or treatment.
Asunto(s)
Humanos , Neoplasias Urogenitales/diagnóstico por imagen , Carcinoma de Células Transicionales/diagnóstico , Neoplasias Urogenitales/complicacionesAsunto(s)
Antineoplásicos/administración & dosificación , Betacoronavirus , Ensayos Clínicos como Asunto/métodos , Infecciones por Coronavirus/epidemiología , Neumonía Viral/epidemiología , Neoplasias Urogenitales/terapia , Procedimientos Quirúrgicos Urogenitales/estadística & datos numéricos , Anciano , COVID-19 , China/epidemiología , Femenino , Humanos , Incidencia , Masculino , Pandemias , SARS-CoV-2 , Resultado del Tratamiento , Neoplasias Urogenitales/complicaciones , Neoplasias Urogenitales/epidemiologíaAsunto(s)
Antineoplásicos Inmunológicos/uso terapéutico , Fallo Renal Crónico/terapia , Neoplasias/tratamiento farmacológico , Diálisis Renal , Enfermedades de las Glándulas Suprarrenales/inducido químicamente , Anciano , Anciano de 80 o más Años , Antígeno B7-H1/antagonistas & inhibidores , Antígeno CTLA-4/antagonistas & inhibidores , Carcinoma de Células de Merkel/complicaciones , Carcinoma de Células de Merkel/tratamiento farmacológico , Femenino , Neoplasias de Cabeza y Cuello/complicaciones , Neoplasias de Cabeza y Cuello/tratamiento farmacológico , Humanos , Hipotiroidismo/inducido químicamente , Fallo Renal Crónico/complicaciones , Neoplasias Pulmonares/complicaciones , Neoplasias Pulmonares/tratamiento farmacológico , Masculino , Melanoma/complicaciones , Melanoma/tratamiento farmacológico , Persona de Mediana Edad , Miocarditis/inducido químicamente , Miositis/inducido químicamente , Neoplasias/complicaciones , Neumonía/inducido químicamente , Receptor de Muerte Celular Programada 1/antagonistas & inhibidores , Estudios Retrospectivos , Neoplasias Cutáneas/complicaciones , Neoplasias Cutáneas/tratamiento farmacológico , Resultado del Tratamiento , Neoplasias Urogenitales/complicaciones , Neoplasias Urogenitales/tratamiento farmacológicoRESUMEN
CONTEXT: The coronavirus disease 2019 (COVID-19) pandemic is leading to delays in the treatment of many urologic cancers. OBJECTIVE: To provide a contemporary picture of the risks from delayed treatment for urologic cancers to assist with triage. EVIDENCE ACQUISITION: A collaborative review using literature published as of April 2, 2020. EVIDENCE SYNTHESIS: Patients with low-grade non-muscle-invasive bladder cancer are unlikely to suffer from a 3-6-month delay. Patients with muscle-invasive bladder cancer are at risk of disease progression, with radical cystectomy delays beyond 12 wk from diagnosis or completion of neoadjuvant chemotherapy. Prioritization of these patients for surgery or management with radiochemotherapy is encouraged. Active surveillance should be used for low-risk prostate cancer (PCa). Treatment of most patients with intermediate- and high-risk PCa can be deferred 3-6 mo without change in outcomes. The same may be true for cancers with the highest risk of progression. With radiotherapy, neoadjuvant androgen deprivation therapy (ADT) is the standard of care. For surgery, although the added value of neoadjuvant ADT is questionable, it may be considered if a patient is interested in such an approach. Intervention may be safely deferred for T1/T2 renal masses, while locally advanced renal tumors (≥T3) should be treated expeditiously. Patients with metastatic renal cancer may consider vascular endothelial growth factor targeted therapy over immunotherapy. Risks for delay in the treatment of upper tract urothelial cancer depend on grade and stage. For patients with high-grade disease, delays of 12 wk in nephroureterectomy are not associated with adverse survival outcomes. Expert guidance recommends expedient local treatment of testis cancer. In penile cancer, adverse outcomes have been observed with delays of ≥3 mo before inguinal lymphadenectomy. Limitations include a paucity of data and methodologic variations for many cancers. CONCLUSIONS: Patients and clinicians should consider the oncologic risk of delayed cancer intervention versus the risks of COVID-19 to the patient, treating health care professionals, and the health care system. PATIENT SUMMARY: The coronavirus disease 2019 pandemic has led to delays in the treatment of patients with urologic malignancies. Based on a review of the literature, patients with high-grade urothelial carcinoma, advanced kidney cancer, testicular cancer, and penile cancer should be prioritized for treatment during these challenging times.
Asunto(s)
Betacoronavirus , Infecciones por Coronavirus/complicaciones , Manejo de la Enfermedad , Pandemias , Neumonía Viral/complicaciones , Tiempo de Tratamiento/organización & administración , Triaje/organización & administración , Neoplasias Urogenitales/terapia , COVID-19 , Terapia Combinada/métodos , Infecciones por Coronavirus/epidemiología , Humanos , Neumonía Viral/epidemiología , Factores de Riesgo , SARS-CoV-2 , Neoplasias Urogenitales/complicaciones , Neoplasias Urogenitales/diagnósticoAsunto(s)
Betacoronavirus , Infecciones por Coronavirus/complicaciones , Manejo de la Enfermedad , Encuestas Epidemiológicas , Oncología Médica/organización & administración , Oncólogos/estadística & datos numéricos , Neumonía Viral/complicaciones , Neoplasias Urogenitales/complicaciones , COVID-19 , Infecciones por Coronavirus/epidemiología , Salud Global , Humanos , Italia , Pandemias , Neumonía Viral/epidemiología , SARS-CoV-2 , Encuestas y Cuestionarios , Neoplasias Urogenitales/epidemiología , Neoplasias Urogenitales/terapiaRESUMEN
Mowat-Wilson syndrome (MWS) is characterized clinically by a distinctive facial gestalt, intellectual disability, microcephaly, epilepsy, and nonobligatory congenital malformations such as Hirschsprung disease, urogenital anomalies, congenital heart disease, eye malformations. This article summarized the clinical features and molecular findings of 15 Chinese MWS patients. The results revealed a higher incidence of congenital heart disease in Chinese MWS patients compared to that previously reported in Caucasian cohorts, while the incidence of Hirschsprung disease and genitourinary malformation appeared to be lower. This suggests possible ethnicity-related modifying effects in the MWS phenotype.
Asunto(s)
Cardiopatías Congénitas/genética , Enfermedad de Hirschsprung/genética , Discapacidad Intelectual/genética , Microcefalia/genética , Adolescente , Adulto , Niño , Preescolar , China/epidemiología , Facies , Femenino , Cardiopatías Congénitas/complicaciones , Cardiopatías Congénitas/patología , Enfermedad de Hirschsprung/complicaciones , Enfermedad de Hirschsprung/patología , Humanos , Discapacidad Intelectual/complicaciones , Discapacidad Intelectual/patología , Masculino , Microcefalia/complicaciones , Microcefalia/patología , Proteínas Represoras , Neoplasias Urogenitales/complicaciones , Neoplasias Urogenitales/genética , Neoplasias Urogenitales/patología , Adulto JovenRESUMEN
This study describes what gynecological (GYN) cancer survivors relate about their intimate partners and adjustments in their sexual lives following diagnosis and treatment. Conventional descriptive content analysis was used to examine participant responses about partner relationships following their diagnosis. Responses revealed three clusters and 15 codes of data. Findings report the influence of cancer treatment on sexual activity and functioning, women's sex lives, and their relationships. Health-care providers have a vital role in supporting women and their partners during the cancer care trajectory and should include both the survivor and the partner in conversations focused on sexual concerns and sexual well-being.
Asunto(s)
Supervivientes de Cáncer/psicología , Conducta Sexual/psicología , Parejas Sexuales/psicología , Neoplasias Urogenitales/psicología , Adulto , Femenino , Humanos , Relaciones Interpersonales , Persona de Mediana Edad , Disfunciones Sexuales Fisiológicas/psicología , Disfunciones Sexuales Psicológicas/psicología , Neoplasias Urogenitales/complicacionesRESUMEN
Patients with chronic disease and mental illness are at higher risk of depression and suicide. Many who have been diagnosed with genitourinary cancers are at higher risk of suicide, even among those who have sought out mental health services. Under-represented populations (African-American, Hispanic, elderly, disabled) suffer disproportionately from a lack of mental health services. However, not much is reported on the interplay of mental health and genitourinary cancer in these populations. This review aims to identify the relevant literature and describe a path forward to address and alleviate this disparity. PATIENT SUMMARY: Patients with chronic disease and mental illness are at higher risk of depression and suicide. Little is known about the complex interplay between race and mental health in patients with urologic cancers and more research is needed.
Asunto(s)
Disparidades en Atención de Salud , Trastornos Mentales/diagnóstico , Trastornos Mentales/terapia , Grupos Raciales , Neoplasias Urogenitales/psicología , Humanos , Trastornos Mentales/complicaciones , Neoplasias Urogenitales/complicacionesRESUMEN
Urologists should optimize personalized care for individuals with a mental health illness following diagnosis of a genitourinary malignancy, be mindful of psychiatric wellbeing, and involve mental health specialists at the earliest opportunity to improve primary and secondary treatment outcomes.
Asunto(s)
Suicidio , Neoplasias Urogenitales/psicología , Humanos , Trastornos Mentales/complicaciones , Factores de Riesgo , Suicidio/estadística & datos numéricos , Neoplasias Urogenitales/complicacionesAsunto(s)
Adenocarcinoma Sebáceo/complicaciones , Neoplasias Gastrointestinales/complicaciones , Síndrome de Muir-Torre/complicaciones , Neoplasias de las Glándulas Sebáceas/complicaciones , Neoplasias Urogenitales/complicaciones , Femenino , Humanos , Estimación de Kaplan-Meier , Masculino , Programa de VERF , Tasa de Supervivencia , Estados UnidosRESUMEN
OBJECTIVES: Malnutrition is frequent in patients with cancer and is associated with a higher rate of morbidity and mortality. However, a significant number of patients at nutritional risk remain undetected due to the lack of a routine screening procedure during diagnosis. Costa del Sol Hospital in Marbella (Málaga), Spain has implemented a protocol for outpatients with cancer aimed at identifying and treating malnutrition at an early stage. The aim of this study was to determine the prevalence of nutritional risk and the rate of malnutrition when cancer is diagnosed. METHODS: We conducted a complete assessment of the nutritional status of patients with cancer of the upper digestive tract (esophagus, stomach, pancreas, or biliary tract) or head and neck cancer. Using the Nutriscore tool at the first oncology consultation, a screening for nutritional risk was performed for patients with other solid tumors. When nutritional risk was detected, a complete nutritional assessment was conducted. RESULTS: Of 295 consecutive patients, 21.4% were found to be at nutritional risk (Nutriscore ≥5). After complete assessment, a moderate degree of malnutrition was observed in 76% and severe malnutrition in 12%. Among patients with colorectal cancer or tumors of gynecologic origin, only 7.5% presented nutritional risk, but 52.8% presented cachexia. CONCLUSION: The high rate of malnutrition observed and the identification of cachexia at an early stage highlight the importance of obtaining early identification of patients at risk to improve the efficacy of nutritional interventions.
Asunto(s)
Desnutrición/terapia , Tamizaje Masivo , Neoplasias/complicaciones , Evaluación Nutricional , Estado Nutricional , Pacientes Ambulatorios , Anciano , Caquexia/epidemiología , Caquexia/etiología , Protocolos Clínicos , Neoplasias Colorrectales/complicaciones , Neoplasias Colorrectales/diagnóstico , Neoplasias del Sistema Digestivo/complicaciones , Neoplasias del Sistema Digestivo/diagnóstico , Diagnóstico Precoz , Femenino , Neoplasias de Cabeza y Cuello/complicaciones , Neoplasias de Cabeza y Cuello/diagnóstico , Humanos , Masculino , Desnutrición/diagnóstico , Desnutrición/epidemiología , Desnutrición/etiología , Persona de Mediana Edad , Neoplasias/diagnóstico , Prevalencia , Derivación y Consulta , Medición de Riesgo , España/epidemiología , Neoplasias Urogenitales/complicaciones , Neoplasias Urogenitales/diagnósticoRESUMEN
Introducción. Los cánceres nefrourológicos constituyen un conjunto heterogéneo y cada vez más frecuente de tumores malignos que poseen el potencial de derivar directamente, e indirectamente por el tratamiento aplicado, en una serie de complicaciones neurológicas que impactan negativamente sobre la calidad de vida de los pacientes. Objetivo. Exponer los datos más relevantes sobre las principales complicaciones neurológicas de los cánceres nefrourológicos. Desarrollo. Búsqueda de artículos en PubMed, últimos libros y principales guías de práctica clínica y sociedades científicas publicados referentes al diagnóstico y tratamiento de dichas complicaciones. Conclusiones. Las complicaciones neurológicas de los cánceres nefrourológicos generan una carga importante de morbimortalidad en los pacientes oncológicos. Paradójicamente, gracias al aumento de su supervivencia, también se incrementa la probabilidad de producirse metástasis en el sistema nervioso o efectos adversos por el tratamiento, en especial la quimioterapia. Actualmente, el diagnóstico y el tratamiento de las complicaciones neurológicas asociadas a los cánceres nefrourológicos suponen un área muy importante de interés creciente para el desarrollo de trabajos de investigación que permitan mejorar el pronóstico y la calidad de vida de estos pacientes y de sus familiares o cuidadores. Para ello, es preciso conocer mejor la etiopatogenia y la fisiopatología que llevan a la aparición de este tipo de complicaciones, particularmente los síndromes paraneoplásicos, y, por otro lado, la realización de ensayos clínicos controlados, aleatorizados, bien diseñados, que amplíen el arsenal terapéutico con nuevos fármacos quimioterápicos con mayor efectividad antineoplásica y mejor seguridad relativa a los efectos secundarios neurotóxicos
Introduction. Genitourinary cancers constitute a heterogeneous and increasingly frequent group of malignant tumors that have the potential to derive directly, or indirectly from the treatment applied, in a series of neurological complications that negatively impact on the quality of life of the patients who suff er them. Aims. To report the most relevant data on the main neurological complications of genitourinary cancers. Development. We conducted a PubMed search for articles, latest books, leading clinical practice guidelines, and scientific societies, regarding the appearance of such complications. Conclusions. Neurological complications of genitourinary cancers generate a signifi cant burden of morbidity and ortality in cancer patients. In a paradoxical manner, owing to the raised survival of these patients, the likelihood of metastatization at the nervous system level and/or adverse eff ects related to the treatment received, especially due to chemotherapy, is also increased. Currently, diagnosis and management of neurological complications associated with genitourinary cancers represent a very important area of growing interest for the development of research projects that allow to improve the prognosis and quality of life genitourinary cancers subjects and their relatives and/or caregivers. For this purpose, it is necessary to know more about the etiopathogenesis and pathophysiology that lead to the occurrence of these type of complications in genitourinary cancers individuals, in particular paraneoplastic syndromes. Moreover, on the other hand, to carry out further well-designed randomized controlled clinical trials that expand the therapeutic arsenal with new chemotherapeutic drugs that possess a better antineoplastic eff ectiveness and improve the safety related to the neurotoxic side effects
Asunto(s)
Humanos , Enfermedades del Sistema Nervioso/complicaciones , Enfermedades del Sistema Nervioso/etiología , Neoplasias Urogenitales/complicaciones , Síndromes Paraneoplásicos del Sistema Nervioso/etiología , Riñón/patología , Vejiga Urinaria/patología , Síndromes Paraneoplásicos del Sistema Nervioso/patología , Metástasis de la Neoplasia , Cerebro/patologíaRESUMEN
PURPOSE OF REVIEW: Targeted therapy for genitourinary cancer is being used at an increasing rate. These medications show great survival benefit but are relatively lacking in long-term adverse effect data. With increasing survivability, measures to improve quality of life must be considered for GU cancer and a large proponent of this is sexual function. RECENT FINDINGS: mTOR inhibitors have shown an effect on testosterone levels and may have a link to abnormal semen parameters. Tyrosine kinase inhibitors (TKIs) have shown no adverse sexual outcomes in the literature. There are laboratory links to tyrosine kinases having a beneficial effect on erectile and sexual function. Possible sexual side effects must be discussed with patients receiving a diagnosis of cancer. Further research is required to determine the exact mechanisms and outcomes of sexual function with new and emerging targeted therapy.
Asunto(s)
Terapia Molecular Dirigida/efectos adversos , Inhibidores de Proteínas Quinasas/efectos adversos , Disfunciones Sexuales Fisiológicas/inducido químicamente , Neoplasias Urogenitales/complicaciones , Neoplasias Urogenitales/tratamiento farmacológico , Animales , Fertilidad , Humanos , Masculino , Erección Peniana , Inhibidores de Proteínas Quinasas/uso terapéutico , Calidad de Vida , Sexualidad , Serina-Treonina Quinasas TOR/antagonistas & inhibidoresRESUMEN
Contesxto: La braquiterapia con alta tasa de dosis (HDR-BT) es un tratamiento de uso creciente en pacientes con cáncer de próstata (CP) localizado. Objetivo: Evaluar la eficacia y seguridad de HDR-BT como monoterapia en CP. Adquisición de evidencia: Revisión sistemática de la literatura mediante búsqueda en MEDLINE (PubMed), Cochrane Library, CDR, Clinicaltrials y EuroScan. Se evaluaron indicadores de eficacia y de seguridad. Síntesis de evidencia: Fueron seleccionadas 2 revisiones y 12 estudios no controlados, incluidos en estas 2revisiones. En términos de eficacia, el control local en 6 estudios es 97-100%. La supervivencia libre de progresión bioquímica varía: 85-100% en riesgo bajo y 79-92% en riesgo alto. La supervivencia libre de metástasis es >95% a 8 años, salvo en un estudio que es 87% a 5 años. La supervivencia global es ≥95% en 8 estudios. En relación con la seguridad, la mayoría de los estudios recogen complicaciones genitourinarias y gastrointestinales agudas y a largo plazo, especialmente de grado ≥ 2. Solo 3 estudios encuentran complicaciones grado 4. Excepto uno (sin complicaciones), en los 11 restantes las complicaciones complicaciones genitourinarias son más frecuentes y más graves que las gastrointestinales. Dos estudios evalúan la calidad de vida y muestran un descenso inicial en distintos dominios y posterior recuperación parcial o total, salvo en la esfera sexual. Conclusiones: La HDR-RT como monoterapia es eficaz, especialmente en riesgo bajo e intermedio. No existe suficiente información en pacientes de riesgo alto. La toxicidad a corto-medio plazo es aceptable. Consideramos necesario potenciar la investigación que aporte más información sobre eficacia y seguridad a largo plazo de este tratamiento
Context: High-dose rate brachytherapy (HDR-BT) is an increasingly popular treatment for patients with localised prostate cancer (PC). Objective: To assess the safety and efficacy of HDR-BT as monotherapy in PC. Acquisition of evidence: A systematic literature review was conducted through searches on MEDLINE (PubMed), Cochrane Library, CDR, ClinicalTrials and EuroScan. We assessed safety and efficacy indicators. Summary of the evidence: We selected 2 reviews and 12 uncontrolled studies, included in these 2 reviews. In terms of efficacy, local control in 6 studies was 97-100%. The biochemical progression-free survival varied as follows: 85-100% for low risk and 79-92% for high risk. Survival free of metastases was >95% at 8 years, except in one study where the survival rate was 87% at 5 years. The overall survival was ≥95% in 8 studies. In terms of safety, most of the studies recorded acute and long-term genitourinary and gastrointestinal complications, especially grade ≥2. Only 3 studies found grade 4 complications. All studies, except for one without complications, observed genitourinary complications that were more frequent and severe than the gastrointestinal complications. Two studies assessed the quality of life and showed an initial reduction in various domains and subsequent partial or total recovery, except in the sexual domain. Conclusions: HDR-BT is effective as monotherapy, especially in cases of low to intermediate risk. There is insufficient information on high-risk patients. The short to medium-term toxicity was acceptable. Further research needs to be funded to provide more information on the long-term safety and efficacy of this treatment
Asunto(s)
Humanos , Masculino , Braquiterapia/instrumentación , Braquiterapia/métodos , Neoplasias de la Próstata/radioterapia , Neoplasias Urogenitales/complicaciones , Neoplasias Urogenitales/radioterapia , Enfermedades Urogenitales Masculinas/patología , Enfermedades Urogenitales Masculinas/radioterapia , Resultado del Tratamiento , Evaluación de Eficacia-Efectividad de Intervenciones , Cuidados a Largo Plazo/métodosRESUMEN
Sexual health is an integral component of quality of life for cancer survivors, and is often negatively impacted by treatment. Geographic limitations often prohibit survivors from accessing sexual health programs designed to address their needs. This study examined the efficacy of an online, 12-week psychoeducational program, which included elements of mindfulness meditation, for sexual difficulties in survivors of colorectal or gynecologic cancer. Complete pre- and postintervention data were available for 46 women (mean age 55.0, SD 9.6) and 15 men (mean age 59.7, SD 6.8). Women experienced significant improvements in sex-related distress (p < .001), sexual function (p < .001 and p < .01), and mood (p < .001); these results were maintained at six months follow-up. Men's improvement in desire was not significant (p = .06), whereas intercourse satisfaction was (p < .05) immediately after the program, but not at follow-up. In order to more fully explore women's experiences, interviews were carried out with six participants and analyzed using narrative inquiry. Women shared a feeling of renewed hope for regaining their sex lives, and expressed that they would have valued an interactive component to the program. These findings suggest that an online, unidirectional psychoeducational program is feasible, and may be effective for women survivors of gynecologic and colorectal cancer, but further work is needed to ensure that online interventions address the sexual health needs of male survivors.
Asunto(s)
Supervivientes de Cáncer/psicología , Meditación , Educación del Paciente como Asunto/métodos , Disfunciones Sexuales Fisiológicas/terapia , Disfunciones Sexuales Psicológicas/terapia , Terapia Asistida por Computador/métodos , Adulto , Supervivientes de Cáncer/educación , Neoplasias Colorrectales/complicaciones , Femenino , Humanos , Internet , Masculino , Persona de Mediana Edad , Calidad de Vida/psicología , Disfunciones Sexuales Fisiológicas/etiología , Disfunciones Sexuales Fisiológicas/psicología , Disfunciones Sexuales Psicológicas/etiología , Disfunciones Sexuales Psicológicas/psicología , Neoplasias Urogenitales/complicacionesRESUMEN
The use of targeted therapies in patients with genitourinary malignancies has significantly improved outcomes. For example, androgen receptor (AR) pathway inhibitors have improved outcomes for patients with prostate cancer, and antiangiogenic agents have improved outcomes for those with kidney cancer. However, these advances have been accompanied by musculoskeletal side effects that manifest as physical dysfunction. Although the effects of androgen deprivation therapy on skeletal muscle are well-known, an additional concern is that the muscle loss associated with these newer drugs-especially AR pathway inhibitors-may result in insulin resistance and metabolic syndrome, thus increasing the risk for cardiovascular events and diabetes. Antiangiogenic agents also may cause muscle loss, although this has been poorly described in the literature. As these targeted therapies begin to be used in the earlier stages of treatment, there will be a critical need to prevent treatment-related toxicities with nonpharmacologic interventions. Over the past decade, exercise training has emerged as a novel nonpharmacologic adjunctive method to address toxicities resulting from these targeted therapies. Despite numerous studies in patients with prostate cancer, there remains a large gap in our knowledge of the true efficacy of exercise therapy, as well as the best way to prescribe exercise programs. Here, we suggest that the central role of skeletal muscle in the development of side effects of AR pathway inhibitors and antiangiogenic agents may unlock a number of unique opportunities to study how exercise prescriptions can be used more effectively. Resistance training may be a particularly important modality.
Asunto(s)
Trastornos Musculares Atróficos/etiología , Trastornos Musculares Atróficos/terapia , Entrenamiento de Fuerza , Neoplasias Urogenitales/complicaciones , Antagonistas de Andrógenos/efectos adversos , Antagonistas de Andrógenos/uso terapéutico , Antineoplásicos Hormonales/efectos adversos , Antineoplásicos Hormonales/uso terapéutico , Humanos , Terapia Molecular Dirigida , Músculo Esquelético/efectos de los fármacos , Músculo Esquelético/patología , Músculo Esquelético/fisiopatología , Estadificación de Neoplasias , Inhibidores de Proteínas Quinasas/uso terapéutico , Resultado del Tratamiento , Neoplasias Urogenitales/diagnóstico , Neoplasias Urogenitales/tratamiento farmacológico , Neoplasias Urogenitales/mortalidadRESUMEN
PURPOSE OF REVIEW: Heavy menstrual bleeding is common among adolescent and young adult women, and can affect health-related quality of life. The cause of heavy menstrual bleeding is not uncommonly because of an underlying hematologic or oncologic disease process, which substantially influences the way patients are counseled and treated. RECENT FINDINGS: Options for menstrual management are more numerous today than ever before and range from minimizing monthly blood loss to suppressing the cycle altogether. However, an underlying bleeding disorder or malignancy can introduce many nuances and limits in individual patient care, which this review highlights. Additionally, because survival rates for adolescent and young adult cancers are improving, more of these patients are planning for lives after their disease, which may include starting or adding to a family. Options for fertility preservation during cancer therapy regimens are solidifying and both primary practitioners and subspecialists should be aware of the possibilities. SUMMARY: Patients with underlying hematologic or oncologic disease require management of menstrual bleeding, but also deserve a comprehensive evaluation and counseling regarding their individualized contraceptive needs and fertility preservation options during their reproductive years. This review employs the latest evidence from current literature to help guide clinicians caring for this unique demographic.